Vadastuximab is a novel antibody-drug compound representing a crucial advancement in the treatment of acute myeloid leukemia (AML). This pioneering therapy precisely targets CD33, a marker frequently found https://minayucg749401.blog5.net/92148696/vadastuximab-a-deep-examination-into-cd33-targeted-therapy